IL-17 Antagonist

Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation.

HB-0043 is a IL-17A and IL-36R antagonist. HB-0043 blocks IL-17A- and IL-36R-mediated signaling pathways, inhibits the production of inflammatory cytokines, and reduces the secretion of pro-inflammatory cytokines IL-6 and IL-8. HB-0043 alleviates skin thickening and inflammatory responses in oxazolone-induced and Imiquimod (HY-B0180)-induced skin reaction mouse models. HB-0043 is applicable for the research of atopic dermatitis and psoriasis.

IL-17A antagonist 1 is an interleukin-17A (IL-17A) antagonist with an IC₅₀ of 1.14 μM and a K_d of 0.66 μM. IL-17A antagonist 1 binds specifically and exclusively to the IL-17A homodimer at its central dimer interface pocket, induces a large conformational change that widens the pocket, and disrupts the IL-17A/IL-17RA interaction. IL-17A antagonist 1 does not bind to IL-17F or IL-17RA.

Simepdekinra (LY4100511; DC-853) is an IL-17A antagonist. Simepdekinra can be used in the research of moderate to severe plaque-type psoriasis.

Erepdekinra is an interleukin-17A (IL-17A) receptor antagonist.

IL-17A antagonist 3 is an IL-17A antagonist, compound 3.

ANB004 is a humanized monoclonal antibody inhibitor, targeting IL-17. ANB004 can be used for autoimmune and inflammatory diseases like multiple sclerosis and rheumatoid arthritis (RA) research.